ClinicalTrials.gg
CompletedNCT03439878Updated May 24, 2018

Effect of Galactose Ingestion on Postprandial Lipemia

An interventional study of Galactose and Glucose in Cardiovascular Risk Factor and Lipemia, sponsored by University of Bath. Completed at 1 site in United Kingdom. Open to male participants aged 18 Years to 35 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2018-05-24.

Sponsored by University of Bath · Not applicable, Interventional, and Basic science

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
10
Allocation
Randomized
Ages
18 Years to 35 Years
Sex
Male
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 40 studies in Hyperlipidemias with a site in United Kingdom — 3 open to participants now, 4 under way, 3 of them phase 3. Hyperlipidemias · United Kingdom.

Enrollment
37th of 39
10 · median 307
Started
2018
the only one that year
No phase
10 of 40
none open now
Registered
29th of 40
by date
Lead sponsor
2 of 40
University of Bath

Among the 40 studies in Hyperlipidemias with a site in United Kingdom, this one is the 37th largest by enrollment of the 39 interventional ones that give a count, is the only one that started in 2018, is one of 10 with no phase, and was the 29th registered.

Hyperlipidemias

863 studies on the registry are indexed under Hyperlipidemias; 109 are open to participants now.

Browse Hyperlipidemias studies →

Open to participants now

3 of the 40 studies in Hyperlipidemias with a site in United Kingdom are open now. Recruiting first, the newest first:

All 3 open studies →

A study can be open while its sites in United Kingdom have not opened yet or have stopped. Only those recruiting at a site in United Kingdom →

Who these studies take

Of the 66 Hyperlipidemias studies recruiting now, 26 (39%) set no upper age limit and 32 (48%) stop at 75 or younger; 8 take children under 18; 16 take healthy volunteers.

This study: 18 Years to 35 Years · male · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 40 studies in Hyperlipidemias with a site in United Kingdom, or all of them as a file.
02

Study summary

This study aims to assess the postprandial triglyceride response to the ingestion of a high-fat meal with co-ingestion of either galactose, or glucose.

03

Conditions studied

  • Cardiovascular Risk Factor
  • Lipemia

Browse trials for

04

Who can participate

Ages eligible
18 Years to 35 Years
Sexes eligible
Male
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male
  • 18 to 35 years old
  • \<30 kg/m2

Exclusion criteria

Exclusion Criteria:

  • Female
  • >29.9 kg/m2
  • Any history of metabolic disease
  • Allergies or intolerances to milk and/or cream
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

05

Study design

Phase
Not applicable
Primary purpose
Basic science
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Double (Participant, Outcomes assessor)
Enrollment
10 participants (actual)

Study arms

  • Experimental
    Galactose

    Ingestion of 0.75 g/kg body mass of d-galactose monohydrate co-ingested with cream to provide 1 g/kg body mass of fat.

    Dietary Supplement: Galactose

  • Active comparator
    Glucose

    Ingestion of 0.75 g/kg body mass of dextrose monohydrate co-ingested with cream to provide 1 g/kg body mass of fat.

    Dietary Supplement: Glucose

Interventions

  • Dietary supplementGalactose

    Co-ingestion of d-galactose with a high-fat meal

  • Dietary supplementGlucose

    Co-ingestion of d-glucose with a high-fat meal

06

What researchers measure

Primary outcomes

  1. Postprandial increase plasma triglyceride concentrations

    Incremental area under the curve (iAUC) of plasma triglyceride concentrations

    Time frame: 5 hours

Secondary outcomes

  1. Postprandial plasma insulin concentrations

    Incremental area under the curve (iAUC) of plasma insulin concentrations

    Time frame: 5 hours

  2. Postprandial plasma glucose concentrations

    Incremental area under the curve (iAUC) of plasma glucose concentrations

    Time frame: 5 hours

  3. Postprandial plasma non-esterified fatty acid concentrations

    Postprandial area under the curve of non-esterified fatty acid concentrations

    Time frame: 5 hours

  4. Postprandial plasma lactate concentrations

    Incremental area under the curve (iAUC) of plasma lactate concentrations

    Time frame: 5 hours

  5. Postprandial subjective hunger ratings

    Postprandial area under the curve of hunger ratings measured by visual analogue scales (0-100 mm)

    Time frame: 5 hours

  6. Postprandial subjective fullness ratings

    Postprandial area under the curve of fullness ratings measured by visual analogue scales (0-100 mm)

    Time frame: 5 hours

  7. Postprandial subjective satisfaction ratings

    Postprandial area under the curve of satisfaction ratings measured by visual analogue scales (0-100 mm)

    Time frame: 5 hours

  8. Postprandial prospective food consumption ratings

    Postprandial area under the curve of prospective food consumption ratings measured by visual analogue scales (0-100 mm)

    Time frame: 5 hours

  9. Postprandial overall appetite ratings

    Postprandial area under the curve of overall appetite ratings measured by visual analogue scales (0-100 mm)

    Time frame: 5 hours

07

Study locations

1 site
  • Department for Health, University of Bath
    Bath, BA2 7AY, United Kingdom
08

References and documents

Publications

  • Watkins J, Simpson A, Betts JA, Thompson D, Holliday A, Deighton K, Gonzalez JT. Galactose Ingested with a High-Fat Beverage Increases Postprandial Lipemia Compared with Glucose but Not Fructose Ingestion in Healthy Men. J Nutr. 2020 Jul 1;150(7):1765-1772. doi: 10.1093/jn/nxaa105. PubMed 32297937 ↗

Individual participant data

Plan to share: No — Raw data will be made available online upon publication in a peer-reviewed journal.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Feb 2018 to primary completion in May 2018, 3 months.

Of 166 non-industry interventional studies with no phase under Hyperlipidemias, half reached primary completion within 16 months of starting (the median), counting those still running; a quarter within 7 and three quarters within 31. This study's 3 months is below that.

Counting every sponsor, half of 171 studies reached it within 15 months; a quarter within 7 and three quarters within 31.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 14, 2018
First posted
Feb 20, 2018
StartActual
Feb 1, 2018
Primary completionActual
May 1, 2018
CompletionActual
May 1, 2018
Last update
May 24, 2018
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 24, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03439878
Lead sponsor
University of Bath
Responsible party
Javier Gonzalez (Associate Professor, University of Bath) — Principal investigator
First posted
Feb 20, 2018
Start date
Feb 1, 2018
Primary completion
May 1, 2018
Completion
May 1, 2018
Last update
May 24, 2018

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Galactose

Start the discussion